IMUNON announced a transition in its financial leadership, with Jeffrey Church retiring as interim CFO effective July 1, 2026. He is succeeded by Josh Blacher, a seasoned life sciences financial executive, who will serve as the company's new interim CFO, principal financial officer, and principal accounting officer. Church's departure is a standard retirement with no disagreements with management, and he will remain in an advisory capacity under an amended consulting agreement providing a monthly retainer of $10,000. Blacher steps into the role through a master services agreement with financial advisory firm Danforth Health, where he has served as a consulting CFO for various life sciences companies since 2022, and IMUNON will pay a rate of $475 per hour for his services. The company noted that the appointment was not made pursuant to any outside arrangements and that Blacher has no familial or material financial conflicts of interest with the company or its executives.
Imunon IncCFO transition is a routine financial leadership change with no material impact on operations or strategy.